Dr Abraham undertook her medical training in London, Oxford and Cambridge. She was a Clinical Lecturer at the Kennedy Institute of Rheumatology and undertook her PhD, as a Wellcome Clinical Training Fellow, examining the effect of glucocorticoids on pro-inflammatory intracellular signalling. Her novel finding was that a Dual Specificity Phosphatase (DUSP1) renders partial glucocorticoid resistance (J Exp Med 2006). Her research interests in Basic Science include intracellular signalling regulation, post-transcriptional regulation and RNA stability. She is a recognised specialist in Rheumatology/Immunology, Internal Medicine and has developed novel Clinical trial designs from First in Human to phase 4 clinical trials with monoclonals antibodies, small molecules, vaccines and plasma derived proteins across therapeutic areas.

Dr Abraham has worked in the NHS as a Consultant and also as a Senior Lecturer in Rheumatology at Imperial College. She has held senior leadership roles in the National Institute of Health Research including rheumatology lead, divisional lead and national industry and biosimilars lead. With her interest in translational and experimental medicine, she has developed and published on biomarker/imaging and drug discovery programmes in Psoriatic arthritis (Psa)and Psoriasis (Pso).

Within Pharmaceutical Medicine she has been head of therapeutic strategies in Immunology and has led clinical development across many indications including dermatology, respiratory, neurology, cardiovascular and renal medicine. Additionally, she is engaged in a number of Public and Patient engagement initiatives to help understanding the needs and value of biomedical research and designing patient centric trials. She is a Fellow of the Royal College of Physicians, London and Glasgow. She is also a fellow and past president of the Rheumatology and Immunology Sections of the Royal Society of Medicine. In 2018 Dr Abraham received a Nomination for the Top 50 women Movers and Shakers in BioBusiness.

Ade is a highly experienced Pharmaceutical Physician who specialises in Clinical Development, having joined the pharmaceutical industry more than a decade ago. He obtained his medical degree from the University of Ilorin, Nigeria where he worked for a couple of years before relocating to the United Kingdom. Prior to joining the industry, he worked in the UK’s National Health Service (NHS) for several years in General Medicine. Ade’s first encounter with clinical research was with a leading Virology Research Organisation, where he played an active role in the development of vaccines and antiviral drugs, utilising a range of different human viral challenge models with various strains of respiratory viruses including Influenza, RSV & HRV. From there, he moved on to lead numerous studies on small molecules and biologics with various pharmaceutical companies as well global contract research organizations (CROs), where he gained broad therapeutic experience in respiratory, immunology, gastroenterology, oncology, endocrinology, cardiology, dermatology, musculoskeletal, neurology and neuroscience. He worked in various capacities as Lead Physician, Sub-Investigator, Principal/Chief Investigator and Medical Monitor. During this period, he underwent the Pharmaceutical Medicine Specialist Training (PMST) programme.

He is currently working as an Associate Director, Medical Services at Aixial Group (formerly Cmed Clinical Services). In his role, he is mainly involved in the development on newest innovations in cell & gene therapy, rare disease, and oncology, including recent advancements in targeted radiopharmaceuticals for cancer treatment.

He is a Member of the American Society of Clinical Oncology (ASCO) and a Fellow of the Institute of Clinical Research (FICR).

By achieving this additional Fellowship, Ade is excited to further contribute to FPM’s mission of promoting the highest standards in the development, regulation, and safe use of medicines.

Dr Adeyi would like to thank everyone who has supported him on this journey and made it possible for him to attain this significant milestone, especially his family and colleagues.

Dr Apara is a Distinguished Scientist/Executive Medical Director, Drug Safety, at Merck Inc. USA.

Olatayo has over 15 years of clinical practice experience, working in many countries, including Nigeria, Ireland, and in the UK (NHS).
Olatayo has an extensive background of working in the pharmaceutical industry, he joined the pharmaceutical industry in 2006 and has since worked for many leading global pharmaceutical companies in different capacities.

As a new Fellow of the Faculty of Pharmaceutical Medicine, Olatayo remains committed to the faculty’s mission, to advance the science and practice of pharmaceutical medicine.

Dr Georgios Bakalos has over 20 years of experience in the pharmaceutical industry and clinical research. He earned his Medical Degree from the University of Iasi in Romania, followed by an MSc in International Medicine and Health Crisis Management from the University of Athens, and a PhD in Pharmaco-Epidemiology and Translational Medicine from the University of Thessaly in Greece.

Currently serving as the Senior Vice President and Head of Global Medical Affairs at Novocure, Dr Bakalos has previously held senior roles at Clovis Oncology and F. Hoffmann-La Roche. His extensive experience in medical affairs and clinical development has led to significant advancements in oncology and infectious diseases.

In addition to his industry roles, Dr Bakalos is an Adjunct Lecturer in Pharmaco-Epidemiology at the University of Thessaly, where he is committed to promoting pharmaceutical medicine, fostering innovation, and mentoring future leaders in the field. He is also an active peer reviewer for several scientific journals and leads research projects on adaptive clinical trial design, evidence synthesis, and digital therapeutics.

Dr Bakalos is a Fellow of the Faculty of Pharmaceutical Medicine and a Member of the Research Quality Association, reflecting his dedication to enhancing patient care through strong collaborations between academia and the pharmaceutical industry.

Dr Daak obtained his medical degree (2004) and MSc in Medical Biochemistry (2006) from the University of Khartoum, a PhD (2012) in Biomedical Science from London Metropolitan University and Diploma of Pharmaceutical Medicine from Faculty of Pharmaceutical Medicine of Royal Colleges of Physicians, UK (2022).

Dr Daak has been working at Sanofi as a Senior Clinical Research Director of Immunohematology, he is based in Cambridge, Massachusetts, US. Dr Daak was Assistant Professor of Medical Biochemistry and Senior Register of Chemical Pathology at Faculty of Medicine, University of Khartoum, Sudan and Clinical Attaché, Pediatric hematology, St Mary’s Hospital, Imperial college, London.  Dr Daak was an affiliated Research Professor at the Center of Molecular Biology and Biotechnology (CMBB), Florida Atlantic University (FAU), USA, and Tekemi Research Fellow at Harvard School of Public Health (HSPH).

Dr Daak is a member of the American Society of Haematology (ASH) since 2015, Member of the International Advisory Board of Kumar & Clark’s Clinical Medicine, and Fellow of the Faculty of Pharmaceutical Medicine, the Royal Colleges of Physicians.

Dr Floyd is a clinical pharmacologist and pharmaceutical physician-scientist working in research and development. He studied preclinical medicine at the University of Cambridge, before completing his clinical studies at University College London. After undertaking junior medical jobs at a variety of London teaching hospitals, Dr Floyd read for a PhD in the ‘Proteomics of Aspirin Resistance’ at King’s College London (KCL). Subsequently, Dr Floyd started specialist training in Clinical Pharmacology and Therapeutics and General Internal Medicine at the Royal London and St Bartholomew’s Hospitals. Two years later he returned to KCL as an NIHR Clinical Lecturer, where he undertook research into cardiovascular risk, worked at the MHRA-accredited Phase 1 unit and delivered specialist clinics at Guy’s & St Thomas’s NHS Foundation Trust. During this time, he also worked with the National Institute for Health and Care Excellence and conducted a number of innovate experimental medicine studies to better understand modulators of blood pressure.

On completion of clinical training, Dr Floyd moved into the pharmaceutical industry. He currently works in drug discovery at GSK where he focuses on the translational strategy in early clinical development. In this role he has led teams in multiple therapeutic areas, utilising different drug modalities and across the whole development pathway, from target identification to filing. Dr Floyd is also a visiting Senior Lecturer at KCL, a member of the Royal College of Physicians, and fellow of both the Higher Education Academy and the British Pharmacological Society.

Kandeepan received his Medical Degree from the University of Aberdeen and a Master of Science Degree from the Imperial College School of Medicine. He was also the Faraday Research fellow at the National Heart and Lung Institute, UK.

Following a 10-year career as a physician in the NHS UK, he joined the Global product development team at Roche in 2007. In this role he played a significant role in clinical development with several successful monoclonal antibody medicine submissions to EMA and FDA. In 2010, he moved to Vifor Pharma, Switzerland to become the Global Head of Medical and Clinical Drug Safety, where he played a leadership role in Drug safety & risk management. In 2012, he returned to Roche within Global Medical Affairs as Senior Medical Director Immunology and was subsequently promoted to Group Medical Director Haematology/Oncology. In this role he was also instrumental in building clinical trial collaborations with academic groups and external pharmaceutical companies.

In 2016, he joined MSD as Executive Director, Oncology Therapeutic Area Head, European Clinical Development responsible for Europe, Middle East and Africa regions, where he was involved in the clinical development of anti PD-1 and immuno-oncology pipeline products across multiple tumour indications. In 2020, he joined Seagen, a biotechnology company focused on developing antibody drug conjugates for the treatment of malignancies and was appointed as Vice President, Head of International Medical Affairs. In 2024, following the acquisition of Seagen by Pfizer, he transitioned to the Pfizer Oncology Division and he is now responsible for Oncology medical affairs for International developed markets, China and emerging markets.

He is a Fellow of the Faculty of Pharmaceutical Medicine UK and a member of several international societies, including European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and American Association of Cancer Research (AACR).

Dr Vinicius Gomes de Lima is a pharmaceutical physician who trained in Switzerland and received his MD from the University of Zurich, Switzerland. Dr Gomes de Lima completed his doctorate in Orthopedic Surgery at the University Hospital Zurich and University of Zurich, Faculty of Medicine, followed by a specialization in Pharmaceutical Medicine at the University of Basel. He is both a member and fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians in the UK (FFPM) and the Swiss Society of Pharmaceutical Medicine in Switzerland (SSPM). He completed a post-graduate program in High Impact Leadership at the University of Cambridge and received his MBA degree from the Quantic University in Washington, USA. He is a well-seasoned leader within the pharmaceutical industry and is currently responsible for the Global Medical Affairs function acting as Head of Global Medical Affairs at CSL Vifor. Aside from his contributions to pharmaceutical medicine, Dr Gomes de Lima is a member and active contributor of MAPS (Medical Affairs Professional Society), being part of the Executive Consortium, the EMEA Leadership Team and Co-Chapter Lead of the Swiss and Nordics chapter.

I am a consultant Physician and Professor of Clinical Pharmacology at the Faculty of Medicine, University of Kufa-Iraq.

I had chaired the Dept of Pharmacology and Therapeutics in the period 2005-2020.

I am a Member and Fellow of many organizations and scientific bodies like The Royal College of Physicians of Ireland,FRCP (London,Edinburgh and Glasgow), Fellow of the American College of Physicians and Fellow of the American College of Cardiology, Fellow of the American College of Chest Physicians, Fellow of the International College of Nutrition, Fellow of the Royal College of Pharmaceutical Medicine of the RCP (UK). professional member of the ESC.

I had published 300 scientific papers in peer reviewed journals with more than 7250 citations, journals include American Journal of Physiology,Lancet,BMJ, International journal of cardiology, Cureus, and Heliyon.

I had supervised 100 MSc and PhD students in cardiovascular Pharmacology and internal Medicine.

I, with other researchers had got an American Patent (High serum level of Notch-1 is a marker of resistance to Cisplatin in non small lung cancer).

I am an Editorial board member of many national and international medical journals .

I have got many awards of excellence from the university of Kufa, Alain University, and International College of cardiology.

Dr Mohammad Arif Hossain is an accomplished Medical Doctor and Japanese research scientist specializing in pediatrics and rare diseases, particularly lysosomal storage disorders (LSDs). He completed his MBBS at Rajshahi Medical College in 2004 and earned his PhD from Osaka University School of Medicine in 2014. Dr Hossain is a fellow of the Royal College of Paediatrics and Child Health of the UK, the Royal College of Physicians of Edinburgh, and the Royal College of Physicians and Surgeons of Glasgow.

Since 2021, Dr Hossain has been serving as a Medical and Safety Monitor at JCR Pharmaceuticals Ltd. in Japan. He plays a crucial role in overseeing the medical aspects of clinical trials, ensuring safety and efficacy in new therapies. His research has earned him numerous national and international awards and recognitions, highlighting his significant contributions to understanding and treating rare genetic diseases.

Dr Hossain’s dedication to advancing patient care and his commitment to medical excellence have established him as a leader in pharmaceutical medicine, where he continues to drive innovations in treatment approaches for rare diseases.

Essam Ghazaly Kerwash, MB BCh, MSc, MD/PhD, FHEA, FBPhS, FFPM is a leading senior clinical pharmacology assessor at the MHRA. Essam Obtained his PhD in Clinical Pharmacology from University of London studying the interindividual variabilities in response to anti-cancer drugs. He received post-doctoral training at Barts Cancer Institute where he supported the clinical development of new generation of anti-metabolites with improved efficacy/pharmacokinetics. He performed translational research leading to the discovery of novel biomarkers that can predict activity/toxicity of the cytotoxic agents using metabolomics approach. Essam’s research output has led to medical practice change on many occasions and included around 100 scientific publications. At the MHRA, Essam assessed the clinical pharmacology aspects of license applications to support early patient access to number of innovative medicines. He is a tutor at the DMDG course “Pharmacokinetics in drug discovery” and he delivered lectures and developed MHRA training programmes and masterclasses on Pharmacokinetics and Biosimilars. Essam delivered training to the Royal College of Physicians on drug interactions and Royal College of Obstetrics and Gynaecology on safe use of medicines in Pregnancy. Essam is recognised for expertise in cancer pharmacology, biosimilars, population and physiologically based modelling. Essam contributed to number of regulatory guidelines, and he is currently serving as topic lead for the ICH M15 Model Informed Drug Development (MIDD) guideline. He is co-leading an active research program investigating the use of modelling to support optimisation of the dose for medicines commonly used during pregnancy and lactation. Essam is a review editor in scientific journals, Fellow of the Higher Education Academy and Fellow of the British Pharmacological Society. He received merit awards such as Conquer Cancer the ASCO Foundation merit award.

Dr Farhan Ahmad Khan is a distinguished Professor in the Department of Clinical Pharmacology at JN Medical College Hospital, Aligarh Muslim University, India. With over 16 years of extensive research experience, He has made significant contributions in the field of Clinical Pharmacology. He has mentored numerous undergraduate and postgraduate researchers, fostering a new generation of scholars in his field.

In addition to his academic role, Dr Farhan serves as a Consultant for the Drug & Poison Information Centre at his affiliated hospital. His research interests include Pharmacovigilance, Pharmacogenetics, Rational Use of Medicine, and Antibiotic Resistance.

He is the Chief Editor of the International Archives of BioMedical and Clinical Research and holds editorial board positions in several esteemed international, peer-reviewed medical research journals. His professional affiliations include memberships in prestigious organizations such as the American College of Clinical Pharmacology, the British Pharmacological Society, the International Society of Pharmacovigilance, the UK Pharmacogenetics and Stratified Medicine Network, the Indian Society for Clinical Research, the Asian Council of Science Editors, and the Science Alert Family.

Elected as Education Councillor for the International Union of Basic and Clinical Pharmacology (IUPHAR) Education Committee for the term 2023-2026. Dr Farhan has also served on the Education Committee of the American College of Clinical Pharmacology in 2020. Additionally, he was appointed as Head of the Accreditation Board for the National Association of Pharmacology and Therapeutics in India for a two-year term.

Dr Farhan has been instrumental in coordinating the Adverse Drug Reaction (ADR) Monitoring Centre under the Pharmacovigilance Programme of India (PvPI), Ministry of Health & Family Welfare, Government of India. He has also played a crucial role in developing the hospital drug formulary to meet the institution’s needs.

With substantial administrative experience, Dr Farhan has led his department as head for six years, demonstrating exceptional leadership and commitment to advancing clinical pharmacology.

Tim is a British / Swiss pharmaceutical leader and physician-scientist with extensive experience in medical affairs and commercial roles. He completed undergraduate medical training at Leeds and UCL and worked in postgraduate posts in north London, New Zealand and Switzerland. He is currently a Vice President at Pfizer, leading the Western Europe Cluster medical affairs organisation and is deputy lead of Pfizer Switzerland’s Postgraduate Training Centre for Pharmaceutical Medicine. He spent 10 years in neurosurgery before joining the industry in 2018 and is a passionate advocate of pharmaceutical medicine as a vibrant and inclusive specialty. He settled in Switzerland more than a decade ago and undertook pharmaceutical medicine speciality training in the Swiss system, which included completion of the University of Basel / ECPM diploma.

Dr Luke Kuttschreuter is a pharmaceutical physician with a passion for innovation and patient-centricity. Luke received his medical degree in South Africa with preclinical and clinical distinctions from the University of Cape Town. After an early career mainly in anaesthesia, he moved to the UK where he was a subinvestigator in early phase clinical trials and completed his MSc in Pharmacology, focussed on preclinical target validation in DNA damage repair mechanisms, both at the University of Oxford.

Luke has since worked exclusively for Pfizer Oncology, gaining experience in Medical Affairs and Clinical Development roles. During this time he earned his DPM in 2021 and completed PMST through the Faculty, entering the Specialist Register earlier this year.

Luke’s most passionate work has focussed on patient and caregiver involvement in the design and conduct of clinical research, especially early phase trials and novel pre-approval non-interventional studies, for which he has won multiple company awards. Luke has also led workstreams within the company and collaborated with the ABPI, NHS-England, HRA, and the NCRI on innovative research methods in Early Access settings, optimising the patient experience while ensuring ethical and equitable access.

Being in the first cohort to complete PMST under the new 2021 curriculum, Luke’s passion for education is evident in his contribution to past FPM Education Days, and now as a member of the Board of Examiners and as a PMST Educational Supervisor. His involvement mirrors his gratitude to all those who have supervised and mentored him in his career to date.

In July, Luke will be starting a new role as the Clinical Lead for an AI-powered oncology early development programme at the TechBio, Owkin.

I am pleased to be appointed as a Fellow of the Faculty of Pharmaceutical Medicine. My medical career has encompassed a diverse range of experiences over the past 38 years. Following the completion of my MD at the Hebrew University Jerusalem and residency training in Obstetrics and Gynaecology at Meir Hospital, Israel (1994), I pursued further specialization in reproductive medicine and IVF at Hammersmith Hospital, London. I subsequently served as a Consultant Gynaecologist at Bourn Hall Clinic (1997-2000).

An MBA from a London institution led to a successful transition into pharmaceutical medicine, where I have enjoyed a distinguished career spanning the past 25 years. My experience encompasses a variety of roles within clinical development and medical affairs. Notably, the past decade has seen me establish myself as a well-respected independent pharmaceutical clinician, providing support to companies of all sizes across the UK, EU, and globally. I am particularly motivated by the opportunity to contribute to novel medical developments with a demonstrably positive impact on patient outcomes. Furthermore, I actively participate in the professional development of colleagues through informal mentorship and serve as an appraiser for the Faculty.

As a Fellow, I fully endorse the Faculty’s mission to advance both the scientific foundation and practical application of pharmaceutical medicine. I look forward to continued contributing my expertise and collaborating with this esteemed organization.

Daniel is Executive Medical Director and Global Project Leader, Early Clinical Development, R&D BioPharmaceuticals at AstraZeneca, specialising in Immunology. He was appointed to AstraZeneca in October 2020, before which he was Director, Discovery Medicine at GSK.

Daniel studied medicine at University College London, and was awarded a PhD and Wellcome Trust postdoctoral fellowship for his research on the immunopathogenesis of Crohn’s disease and ulcerative colitis. In parallel, he trained in general medicine and clinical pharmacology at University College London Hospital, during which time he developed his subspecialty interests in drug discovery and clinical trials. In the Faculty, Daniel chairs the group of examiners for the Diploma in Human Pharmacology and Diploma in Experimental Therapeutics. He is also a Fellow of the British Pharmacological Society, and Senior Editor of the British Journal of Clinical Pharmacology.

Alongside his work in drug discovery and development, Daniel remains a consultant physician at University College London Hospital, and an Honorary Associate Professor at University College London.

Hossam Mourad (also called Hussam Murad) holds MD Pharmacology, Faculty of Medicine, Ain Shams University, and MSc Clinical Pathology, Faculty of Medicine, Cairo University, Egypt. Hossam has over 30 years of experience in teaching, research, and clinical work. He taught Pharmacology, Clinical Pharmacy, and Medication safety in a number of universities in Egypt and Saudi Arabia. Currently, he is a Professor of Medical Pharmacology, Faculty of Medicine, Rabigh Campus, King Abdulaziz University, Jeddah, Saudi Arabia. He is a Fellow of the International College of Angiology (Member, Council for International Organizations of Medical Sciences), USA. His research focuses on drug repurposing, developing new pharmaceutical formulations, and searching for novel biomarkers which can predict responses to therapy. Also, his work included evaluating the pharmacological activities of natural compounds as potential therapies for certain diseases or for drug-induced adverse effects, in-silico evaluation of natural or synthetic compounds as potential treatments and studying off-label uses of drugs. He registered two patents at the United States Patent and Trademark Office (USPTO) in 2021 related to developing a new pharmaceutical formulation for treatment of hepatic fibrosis and its duodenal complications in a disease model in rats. His clinical research included studies about drug prescription patterns and medication non-adherence and its association with the readmission rates. Moreover, he developed and validated an Arabic Version of the Drug Abuse Screening Test-10 (DAST-10) in 2021 aiming to get a reliable and valid screening tool for drug use-related problems in Arabic speakers. The test was well-received and till date, Hossam received requests from 16 institutions in eight Arabic countries asking for permission to use it. As a new Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians, UK, he remains committed to its mission, to advance the science and practice of pharmaceutical medicine.

Dr Sumit Munjal graduated as a medical doctor from India and gained clinical experience in the field of Neurosciences in the National Health Service (NHS), UK. He went onto complete a Master’s degree in Epidemiology from London School of Hygiene & Tropical Medicine (LSHTM) and worked in the field of pharmacoepidemiology as a Clinical Research Fellow at the Drug Safety Research Unit (DSRU), Southampton. In 2008, he joined Medicines & Healthcare products Regulatory Agency (MHRA), UK as a Medical Assessor in Vigilance & Risk Management of Medicines and was involved in important drug safety issues such as paracetamol overdose and pack size legislation. Following this, he worked as a Consultant Physician to Janssen Cilag Ltd, Johnson & Johnson in their Global Medical Safety department for Oncology products. In 2012, he joined Takeda Pharmaceuticals and worked his way upwards through various responsibilities. His last position was Takeda Vice President, Global Patient Safety Evaluation and EU/UK Qualified Person responsible for PV. During his time, he also fulfilled the role of Responsible Officer (RO) for Takeda Designated Body for GMC revalidation of physicians. In April 2023, he decided to join Otsuka Pharmaceuticals as Global Head of Medical Safety where he oversees a team of around 100 staff. In terms of academic learning, he is also pursuing an Executive MBA program 2022-2024 from Said Business School, University of Oxford UK. During his time as pharmaceutical physician, he worked closely with the Faculty of Pharmaceutical Medicine (FPM), UK where he has been an appraiser since the start of the GMC revalidation program and contributed as a member of the Ethics and Practice Committee of the FPM UK. He looks forward to his future work as a Pharmaceutical Physician.

After completing his medical studies and a Master’s Degree in Pharmacology in South Africa, Danie spent 3 years working in a primary care setting including his own private practice. He joined the pharmaceutical industry in 1993, worked in Medical Affairs, Marketing and Sales, Pharmacovigilance and Clinical Operations. He held roles of increasing responsibility and leadership, including Senior Vice President and Head of Worldwide Medical Affairs at GlaxoSmithKline. After 4 years as head of Medical Affairs, Danie is now the Executive Vice President Pharmaceutical Operations for Kyowa Kirin International and joined the company in Aug 2019.

He is registered with the medical councils in the UK and South Africa and completed his MBA through Heriot Watt University and Edinburgh Business School in 2006. He is a Director and Chair of the Global non-profit Medical Affairs Professional Society (MAPS) Board, visiting senior lecturer at King’s College, London and an affiliate member of the Association for Professional Executive Coaching and Supervision (APECS).

Professor Syed Ziaur Rahman, an Australian resident of Indian descent, has dedicated over two decades to the field of Pharmacology, boasting extensive research experience in both basic and clinical pharmacology at undergraduate and postgraduate levels. He obtained his MBBS degree in 1995 and MD in 2000 from Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh. His doctoral research, conducted at the School of Medicine, Western Sydney University, Australia, focused on the health, medication, and lifestyle factors impacting self-rated memory, as part of the Sax Institute’s ’45 and Up Study’ project.

Currently, Professor Rahman serves as the Head of the Department of Pharmacology at Aligarh Muslim University. In the realm of Pharmacovigilance, he has pioneered the reporting of several cases of Adverse Drug Reactions (ADRs) and introduced the concept of environmental pharmacovigilance. He has held various positions within the Society of Pharmacovigilance, India (SoPI), presently serving as the National Secretary. Additionally, he coordinates the AMC-PvPI and MDMC-MvPI at JNMC, AMU, Aligarh, under the Indian Pharmacopoeia Commission (IPC).

Professor Rahman’s interests extend to Traditional Medicine, particularly Unani medicine, where he explores topics such as the morphine de-addiction properties of medicinal plants. He has proposed a modified method for inducing morphine dependency in rats of varying severity. He is the founder trustee of Ibn Sina Academy of Medieval Medicine & Sciences at Aligarh, India. The Academy is designated as “Centre of Excellence” by Ministry of AYUSH, Govt. of India. The Academy is also listed in the Directory of History of Medicine Collections by the US Department of Health and Human Services, National Library of Medicine, NIH, USA. Professor Rahman’s contributions include enriching the library of the Academy and establishing the ‘Centre for Advanced Study in Pharmacology’ and the ‘Centre for Safety & Rational Use of Indian Systems of Medicine.’

Physician with specialist training in Clinical Diabetology, an alumnus of Indian Institute of Management Bangalore (IIMB) and Fellow of Clinical Pharmacology (ACCP, USA). With over 2.5 decades of experience in healthcare including the Biopharmaceutical industry across Emerging markets. Practiced clinical diabetology (hospital-based & outpatient practice) in India and Libya. Over 2 decades in Biopharma in medical affairs, clinical development and pharmacovigilance for innovative small molecules, biologics, vaccines, biosimilars, and medical devices across multiple therapeutic areas at Global Pharma majors (AstraZeneca, Novo Nordisk, Novartis, Allergan, AbbVie) & Indian Multinationals (Dr. Reddy’s & Strides Arcolab). Currently working as AA Regional Medical Director – MEA (Middle East & Africa) & Thailand, AbbVie, Dubai, UAE.

Worked on many clinical trials (Phase 1-3 + non interventional studies) & BA/BE studies across TAs. Led design and conduct of many non-interventional studies (RWE) all the way up to their publication. Publications include 5 original articles in peer-reviewed journals; 8 invited articles in reputed international healthcare magazines; 11 podium presentations & 10 posters in international congresses (IDF, ACCA, APCC, AOCN etc.). Over 24 posters in national conferences (>20 published as abstracts in journals). Over 80 lectures in international and national, conferences and seminars across geographies.

Awarded Fellowship of American College of Clinical Pharmacology (ACCP) in 2018 and served on executive committee of South Asia Chapter of ACCP (SAC-ACCP) 2018-2020. Currently serves on Publication committee of the ACCP. Served on the education committee (2019-2020). Recipient of many healthcare awards (Best Citizens of India 2016, Rajiv Gandhi Gold Medal Award 2018, IARDO Award etc.) and Industry awards (e.g. R&D President’s Award 2021; DAPA Star Award 2010; Asia R& D award 2010; MD’s Circle of Excellence 2009). Listed as a Global Pharmaceutical Sciences Experts by www.omiconline.org & featured on cover page of “Start Up City” magazine – ‘Biotech Start-ups edition’ 2019.

Dr Phil Ryan is Medical Director at Nucleus Network in Melbourne, Australia, which runs Phase I first-in-human trials. He joined Nucleus Network in 2021 and has been a principal investigator on over 30 Phase I clinical trials, in a range of therapeutic areas, including neurological, respiratory, infectious disease, immunological, psychiatric, gastrointestinal and cardiovascular. He completed his Diploma of Pharmaceutical Medicine through the Faculty of Pharmaceutical Medicine in 2021.

Phil is a medical doctor and researcher with over 20 years’ experience in health care and neuroscience research. His major interest is the interface between research and clinical medicine. He had extensive experience in general medicine before transitioning into neuroscience lab research, completing a PhD at the University of Melbourne and postdoctoral studies at the University of Washington in Seattle. Recently, he has also been working part-time at the Florey Institute of Neuroscience and Mental Health in Melbourne, where he is Head of the Fluid Homeostasis Group. Here, he uses cutting-edge genetic techniques to investigate the role of distinct brain regions in fluid and food intake, anxiety and addiction.

As a new Fellow of the Faculty of Pharmaceutical Medicine, he is committed to advancing the science and practice of pharmaceutical medicine globally.

A pharmaceutical physician and physician scientist working in the global pharmaceuticals industry over the last 15 years. Currently working in the field of patient safety and public health at CSL, a prestigious more than 100-year-old company specializing in plasma-based biotechnology and vaccines.

Throughout my journey spanning over 15 years, whether in India, Australia, or now in the United States, my passion for improving patient outcomes has remained unwavering. From my early days as a medical reviewer to my recent roles in clinical safety, medical affairs, and beyond, I have consistently sought to push the boundaries of what is possible and make a meaningful impact in the lives of patients worldwide.

My deep connection to a professional body (such as FPM) has always been instrumental in my professional growth and development. From my first boss who introduced me to the industry to my current mentors in the industry and in my organization, I have been fortunate to have had excellent guidance and support along the way. Their wisdom, guidance, and encouragement have been invaluable in shaping my career and fostering my passion for pharmaceutical medicine. Joining the faculty is more than just an accolade for me; it is a beginning of a new chapter and a platform through which I aim to contribute to the advancement of pharmaceutical medicine. As a physician at heart, I wake up every day knowing that my work will impact and improve patient outcomes; and I believe, as Theodore Roosevelt said, “No one cares how much you know, until they know how much you care.”

Leonard Weather Jr., RPh, MD, FAPCR is a gynecologist. He received his BS in Pharmacy from Howard University and his MD from Rush Medical College in Chicago, IL. He completed his internship, residency and fellowship in gynecology and obstetrics at the Johns Hopkins University Hospital, Baltimore, MD. Dr Weather is a health educator and professor, ordained minister, artist, author, and photographer. He has authored three inspirational poetry books, an infertility handbook and his most recent book, (June 2023), is “Endometriosis, the Name of the Pain and How to Repress It.” He is an active gynecological clinical trials researcher, has presented over 210 peer review presentations and papers on pelviscopic surgical treatment of infertility, endometriosis, pelvic pain and fibroids. He invented the surgical procedure Optical Dissection Pelviscopy, to assist in the prevention of organ injury during laparoscopy. Dr Weather is Past President of the National Medical Association, New Orleans Medical Association, and the Louisiana Medical Association. He currently serves as the President of the North Louisiana Medical Association. Additionally, he is a member of the Board of Scientific Advisors to the Endometriosis Association, a Fellow of the Federation of State Medical Boards, a Fellow of the Academy of Physicians in Clinical Research, National President of the Chi Delta Mu Medical Fraternity, Board Member of the Louisiana State Board of Examiners, and a Board Member of the Academy of Physicians in Clinical Research (APCR), Board of Trustees. October 6, 2023, he was elected APCR President. Additionally, December 2023, he was appointed American Medical Association’s Representative to the United States Adopted Name Review Board. (The US Adopted Names (USAN) Council is responsible for selecting informative and unique nonproprietary (generic) drug names. Instances where nomenclature disputes between the USAN Council and applicants cannot be resolved and normal procedures fail, the USAN Review Board is the final arbiter.

Kirsty holds a Bachelor of Science in Biochemistry from Charing Cross and Westminster and a medical degree from Imperial College. She spent nearly 10 years in the NHS, training in Anesthetics and Intensive Care and obtaining Fellowship of the Royal College of Anaesthetists, before joining the pharmaceutical industry. She also has a Masters in Pharmaceutical Medicine (with distinction).

Kirsty initially worked for a medical gases company before joining the Medicines and Healthcare products Regulatory Agency (MHRA) in 2009 as a medical assessor in the Clinical Trials Unit (CTU). In her nearly 14 years at the Agency she became an Expert assessor and Head of Medical Assessment in CTU, building up expertise across all therapy areas and trial phases, but with a particular interest in first-in-human trials and advanced therapies. Drawing on her experience with the use of real-world data, novel trial design, decentralised trials and use of e-technologies, Kirsty led the novel clinical trials response for the MHRA’s commitment in the Life Sciences Industrial Strategy (LSIS) and the Life Sciences Vision and has represented the MHRA in multiple novel trial design projects such as the Clinical Trials Transformation Initiative (CTTI) master protocol project with the FDA and Duke University.

Since 2022 Kirsty has been the Head of Regulatory Strategy at Weatherden, a global integrated clinical consultancy, helping drive regulatory plans for companies in the UK, US, EU and Japan. Kirsty also chairs the Clinical Trial Science and Regulations Expert Group of the Faculty of Pharmaceutical Medicine; is the regulatory strategy and early clinical development expert on the Scientific Advisory Board of CRO Simbec-Orion; a committee member of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI); and a visiting lecturer for King’s College London, covering regulatory aspects across several pharmaceutical MSc courses.